Drugs / Permixon
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02121613 | Apr 2014 → Jun 2016 | benign prostatic hyperplasia | Pierre Fabre Laboratories | Completed | No outcome recorded |
| Phase 4 | NCT01604811 | Jun 2012 → Oct 2013 | benign prostatic hyperplasia | Pierre Fabre Laboratories | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PERMIXON | “PERMIXON® 160 mg Hard Capsule” NCT01604811 ↗ |
| Route | Oral | “Oral administration - 160 mg twice daily.” NCT01604811 ↗ |